Quanta BioDesign, Ltd. was founded for the purpose of developing and commercializing an extensive line of products for companies involved in drug discovery and diagnostic development programs. All of our products are based on our proprietary discrete polyethylene glycol (dPEG®) chemistries, including our processes for making these compounds. Our single molecular weight ethylene glycol conjugation technology, dPEG®, can eliminate common problems found in the development of diagnostic and therapeutic products, such as aggregation and non-specific interactions, poor water solubility, poor delivery, delivery issues/options, short serum half-life, toxicity and antigenicity. The dPEG® product line can be custom tailored to meet specific physical, chemical and morphological requirements in a broad array of diagnostic and therapeutic applications. Quanta BioDesign is involved in developing new cross-linking and labeling chemistries that incorporate the dPEG® technology, and will allow for new approaches in the area of therapeutic and diagnostic development. This LinkedIn page will feature company news and new product announcements. In addition, we will highlight and discuss papers that demonstrate applications of our dPEG® products to solve novel, pressing problems in medical diagnostics, therapeutics, theranostics, nanotechnology, and other fields of research.